Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region. The drugmaker mapped ...
Good day, and welcome to the I-Mab Business Update Call. [Operator Instructions]. As a reminder, this conference call is being recorded and will be available for replay on the company's website. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback